What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?

Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis on 14 October 2026. In the trial, nearly 70% of patients receiving the higher Tezspire dose achieved remission at week 24. The study targeted eosinophilic esophagitis, a chronic inflammatory condition that currently has limited approved treatment options. The Tezspire eosinophilic esophagitis Phase 3 success is only one part of the wider Amgen story investors may want to...